Immunotherapy in head and neck cancer: aiming at EXTREME precision. - Wikidata - awgldk - TriplyDB

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

http://www.wikidata.org/entity/Q33756244

about

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.New developments in the management of head and neck cancer – impact of pembrolizumab.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.Targeting Head and Neck Cancer by Vaccination.

P2860

Q41886564-7CFCBDAC-E3D1-44F1-BE52-532DEAE39047 Q42343618-8DAFDC0E-B954-4182-8ADD-799F22DC1B91 Q49231401-2CB922DF-58A0-4463-B685-E16018B80FDA Q49787173-3B5C95FE-D8EA-4924-AAB6-271D40A44A44 Q50336126-362657D7-78DC-4A65-8F7D-350E45603765 Q52617485-C6CC86E8-AFF4-4F86-A640-BC2DB0B0DE5D Q54217605-733E57B8-87CA-4ACD-A9A6-18F02DF8D81B

P2860

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

http://www.wikidata.org/entity/Q33756244

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@ast

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@en

type

label

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@ast

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@en

prefLabel

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@ast

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@en

P1433

Q33756244-0FC63147-07A6-4C34-A236-0B37F558DE16

P1476

Q33756244-9A83310B-8903-4437-A439-E72A09D648CF

P2093

Q33756244-375B8AB2-06CF-411A-ABF1-10691A536AA0

Q33756244-7ADD4734-8940-4487-AAA5-E0F699C0CB51

P2860

Q33756244-0277FB2B-B5D2-4F6A-8599-A4E97864D32A

Q33756244-038AC631-999E-4BFB-8582-CD7F2374FC16

Q33756244-0913C590-AF4E-44FF-89D3-A084AEE6BB3D

Q33756244-0C4A3129-6062-4895-8CC6-A642C8D19285

Q33756244-10599A47-EAF8-4319-BD75-6B07DE624BCB

Q33756244-15CFACA8-8EB1-4248-BD20-A37D903AA55A

Q33756244-19F6C8BB-E85C-463A-9386-83DEF82726B5

Q33756244-2398137A-0A06-4FDE-A662-828863B5E4B2

Q33756244-241E06E6-2B16-4321-9B1F-0E41CFD64DC1

Q33756244-308F5CC3-921B-476E-BF45-D13D3BF3398B

P2888

Q33756244-9D23BB4F-256A-4187-88DE-8CEF7B8B4941

P304

Q33756244-6AEC3697-AC91-4A8D-9D4E-58C9447DAC6E

P31

Q33756244-77DA6D35-6E44-4AA5-B114-7D063547722C

P356

Q33756244-A69E6033-AC26-4516-A604-5DE96768E683

P407

Q33756244-9D939A69-BFDE-463D-83D9-F22DBE22082B

P433

Q33756244-146B627B-A105-4D36-9D5A-31A15A877FD8

P478

Q33756244-43FE65DC-67A2-4551-A7C0-3203E3437571

P577

Q33756244-D48EB6B0-2610-492B-A56B-BD787B1120FD

P6179

Q33756244-FA3BDBFA-0A10-4D73-B986-2403C60DC465

P698

Q33756244-10FEB8DE-B1D6-4B28-A82C-B74B1414589A

P932

Q33756244-40A45604-87F5-49CA-909A-454115E3C9A1

P356

S12916-017-0879-4

P1433

P1476

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

@en

P2093

Jan B Vermorken

http://www.w3.org/2001/XMLSchema#string

Petr Szturz

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

The role of HPV in head and neck cancer and review of the HPV vaccine

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Cancer immunoediting: from immunosurveillance to tumor escape

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

P2888

s12916-017-0879-4

P304

110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12916-017-0879-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085743212

http://www.w3.org/2001/XMLSchema#string

P698

28571578

http://www.w3.org/2001/XMLSchema#string

P932

5455211

http://www.w3.org/2001/XMLSchema#string